BB Biotech Ventures
BB BIOTECH VENTURES is a healthcare-dedicated venture capital fund, focused on companies that develop and market drugs and medical devices.
Business Model:
Revenue: $10.7M
Employees: 2-10
Rankings
Industries / Tags:
Detailed BB Biotech Ventures Information
Geographic Data
Address: Seestrasse 16
City:
State: zurich
Zip: 8700
Country: CH
Financial Info
Stage:
Raised Last:
$0
Raised Total:$0
Social
Crunchbase
Metrics
0Website Global Rank
0Website Monthly Traffic
Twitter Followers
Description
BB BIOTECH VENTURES is a healthcare-dedicated venture capital fund, focused on companies that develop and market drugs and medical devices. The Guernsey–based fund is advised by the Bellevue Asset Management Group, which has operations in Curaçao, Boston/USA and Kusnacht/Zurich, Switzerland. BB BIOTECH VENTURES has a dedicated team of investment advisors and an advisory board. In addition, it is supported by all of the Group’s health care investment experts, and an extensive network of specialists and advisors. Our goal is to maximize the returns to our investors. To achieve this goal, we combine hard working, experience, networking, and focus on value creation.
Contact Phone:
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 4/2009 | Orthocon | Series B | 25M |
| 8/2007 | Alpex Pharma | Series B | 9M |
| 6/2014 | Natural Dental Implants | Series A | 1.4M |
| 1/2014 | Sonetik | Series A | - |
| 11/2003 | Auxilium Pharmaceuticals | Series D | 43M |
| 4/2009 | Aerovance | Venture Round | 38M |
| 8/2007 | Pevion Biotech | Series A | 29.2M |
| 4/2013 | Radius Health | Private Equity Round | 43M |
| 2/2008 | BioVascular | Series C | 10.9M |
| 9/2011 | AM Pharma | Series D | 39.9M |
| 12/2019 | Aleva Neurotherapeutics | Series E | 8.1M |
| 9/2014 | AM Pharma | Series E | 15.8M |
| 12/2016 | Abyrx | Venture Round | 0 |
| 2/2010 | Tioga Pharmaceuticals | Venture Round | 18M |
| 9/2005 | TargeGen | Series C | 30M |
| 2/2006 | Orthocon | Series A | 10M |
| 8/2009 | Palyon Medical | Series A | 24M |
| 12/2005 | Optimer Pharmaceuticals | Series D | 22.2M |
| 1/2006 | Tioga Pharmaceuticals | Series A | 24M |
| 4/2007 | Radius Health | Series B | 57.5M |
| 11/2009 | Vivoryon Therapeutics | Series B | 0 |
| 1/2012 | Vivoryon Therapeutics | Venture Round | 19.4M |
| 3/2006 | BioXell | Series C | 12.7M |
| 4/2012 | Aleva Neurotherapeutics | Series B | 4.4M |
| 1/2017 | Binx Health | Series D | 0 |
| 10/2013 | Opsona | Series C | 0 |
| 4/2013 | Opsona | Series C | 0 |
| 1/2015 | Binx Health | Series C | 0 |
| 7/2011 | Binx Health | Series B | 27.1M |
| 8/2001 | Eyetech Pharmaceuticals | Series C | 108.5M |
| 7/2011 | Radius Health | Series C | 66M |
| 12/2011 | Radius Health | Private Equity Round | 21.4M |
| 11/2008 | Radius Health | Series C | 15M |
| 12/2009 | Molecular Partners | Series B | 44.2M |
| 9/2022 | Rivus Pharmaceuticals | Series B | 132M |
| 10/2004 | BioXell | Series C | 29M |
| 8/2007 | Molecular Partners | Series A | 15.6M |
| 1/2011 | VAXIMM | Venture Round | 8M |
| 2/2018 | Moderna Therapeutics | Series G | 0 |
| 4/2014 | Binx Health | Series B | 0 |
| 3/2020 | AM Pharma | Venture Round | 25.4M |
| 9/2008 | Lumavita | Series A | 16.2M |
| 7/2007 | TargeGen | Series D | 40M |
| 8/2011 | Aleva Neurotherapeutics | Series A | 13.7M |
| 5/2016 | Aleva Neurotherapeutics | Series C | 18M |
| 3/2020 | AM Pharma | Venture Round | 0 |
| 12/2019 | Aleva Neurotherapeutics | Series E | 0 |
| 2/2018 | Moderna Therapeutics | Series G | 0 |
| 1/2017 | Binx Health | Series D | 0 |
| 12/2016 | Abyrx | Venture Round | 0 |
| 5/2016 | Aleva Neurotherapeutics | Series C | 0 |
| 1/2015 | Binx Health | Series C | 0 |
| 9/2014 | AM Pharma | Series E | 0 |
| 6/2014 | Natural Dental Implants | Series A | 0 |
| 4/2014 | Binx Health | Series B | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
